Dicerna Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Dicerna Pharmaceuticals, Inc., and our comprehensive analysis, click "
Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Dicerna Pharmaceuticals, Inc. | DRNA - NASDAQ |
$11.00-$13.00 |
$15.00 |
$30.00 | 6 million | 1/30/2014 |
Jefferies, Leerink Swann, Stifel |
Co-Manager(s): Baird |
Health Care |
Filing(s): Filed 2013-12-31
|
Dicerna Pharmaceuticals, Inc. Quote & Chart - Click for current quote -
DRNA
About Dicerna Pharmaceuticals, Inc. (adapted from Dicerna Pharmaceuticals, Inc. prospectus):
They are a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
This description is adapted from Dicerna DRNA prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as Dicerna DRNA "DRNA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2025 IPO Boutique. All Rights Reserved